Search Results - endri+karaj

3 Results Sort By:
Metabolically stable HDAC inhibitors with trifluoromethylpyruvamide as metal-binding group
Project ID: TECH-2023-25 Background Histone Deacetylases (HDACs) have been studied extensively for their role in regulating expression of genes and proteins involved in cancer cell proliferation and migration. The Zinc Binding Group (ZBG) is an essential component of the HDAC inhibitor pharmacophore. It binds to the zinc ion in the enzyme active...
Published: 5/21/2024   |   Inventor(s): Liyanaaratchige Tillekeratne, Endri Karaj, Riddhidev Banerjee, William Taylor
Keywords(s):  
Category(s): Oncology
Ferroptosis-HDAC Inhibitor Hybrids for treating cancer
Project ID: D2022-16 Background Many cancer treatments target cells and induce apoptosis, a cell death mechanism. Due to genetic instability, tumors become more heterogeneous leading to cells that avert molecular signatures that are targeted by the cancer drugs. Drug resistance remains a major impediment to the success of a cancer treatment. Combinatorial...
Published: 6/18/2024   |   Inventor(s): Liyanaaratchige Tillekeratne, Endri Karaj, Shaimaa Sindi, William Taylor
Keywords(s): Cancer, Drug-resistance, HDAC inhibitors, Histone deacetylases , Non-apoptotic cell death
Category(s): Oncology
A new class of HDAC inhibitors with a new metal-binding group
Project ID: D2018-08Background Cancer is group of diseases characterized by uncontrolled growth of abnormal cells. Selectivity towards cancer cells has been challenging, resulting in treatment options with severe side effects. Histone deacetylases (HDAC) are highly expressed in cancer cells and have been investigated for cancer drug development. Out...
Published: 6/18/2024   |   Inventor(s): Liyanaaratchige Tillekeratne, Ayad Al-Hamashi, Samkeliso Dlamini, Abdulateef Alqahtani, Endri Karaj
Keywords(s): Cancer, Drug development, GI-50, Histone deacetylases
Category(s): Oncology